ReviewMolecular biology reports2026
Mechanistic insights into the role of salicin in mitigating oxidative and inflammatory pathways of diabetic complications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a rapidly growing global health challenge characterized by persistent hyperglycemia and progressive complications affecting multiple organ systems. Despite the widespread use of conventional antidiabetic therapies, oxidative stress and inflammation persist, contributing to the development and progression of diabetic complications. This therapeutic limitation underscores the need for novel adjunctive strategies, particularly those involving natural bioactive compounds that exhibit antioxidant and anti-inflammatory properties. This review critically evaluates the potential of salicin, a naturally occurring β-glucoside with antioxidant and anti-inflammatory properties predominantly derived from willow bark, in modulating oxidative and inflammatory pathways implicated in diabetic complications. A comprehensive literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar to identify relevant experimental, translational, and clinical studies examining salicin and salicin-rich extracts in the context of diabetes and its complications. The current evidence suggests that salicin exhibits antioxidative and anti-inflammatory effects through multiple molecular and cellular pathways, thereby collectively contributing to improved pathological and metabolic regulation. These biological activities support its potential role in mitigating diabetes-associated tissue damage and position salicin as a promising natural adjunctive candidate for managing diabetes-related complications. However, the majority of evidence originates from in vitro and animal studies, and well-designed clinical investigations addressing long-term safety, optimal dosing, and therapeutic efficacy in diabetes are limited. This research gap underscores the need for rigorous translational and clinical studies to validate salicin's therapeutic potential in the management of diabetes-related complications.
Indexed as
Identifiers
41733755What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.